Chapter review

Fitzgerald PMHNP board review. ch08. Mood Disorders. This is drive 2 of 8. When I say Pause. Answer. wait, then I will give the answer. New section. Depressive disorders: criteria, specifiers, timelines, and differentials. Topic. Depressive Specifiers. Bottom Line Summary. * **Major depressive disorder** severity specifiers are classified as mild, moderate, moderately severe, and severe using validated tools like the **PHQ-9**, where scores of 1 to 4 indicate minimal, 5 to 9 mild, 10 to 14 moderate, 15 to 19 moderately severe, and 20 to 27 severe depression. * **With peripartum onset** specifier requires mood symptom onset during pregnancy or within the initial 4 weeks following delivery. **Interpersonal psychotherapy** is preferred for mild to moderate cases, while **sertraline** or **citalopram** are preferred SSRIs if pharmacotherapy is necessary. * **With psychotic features** specifier indicates severe depression accompanied by mood-congruent or mood-incongruent delusions or hallucinations, requiring combination therapy with an antidepressant and a second-generation antipsychotic, or **electroconvulsive therapy**. * **With seasonal pattern** specifier involves depressive episodes recurring predictably at specific times of the year, most commonly fall or winter, with full remission in spring for at least 2 consecutive years. Treatment includes **bright light therapy** at 10,000 lux for 20 to 30 minutes daily starting in early autumn, **vitamin D** at 2000 to 5000 IU daily, and SSRIs. * **With anxious distress** specifier identifies co-occurring anxiety symptoms during a depressive episode, elevating suicide risk and treatment complexity. **Bupropion** is not recommended **first-line** when severe anxiety or panic is prominent. * **With melancholic features** specifier requires loss of pleasure in all activities or lack of reactivity to usually pleasurable stimuli, accompanied by diurnal variation with depression worse in the morning, early morning awakening at least 2 hours before usual, severe psychomotor agitation or retardation, significant anorexia or weight loss, and excessive guilt. * **With atypical features** specifier features mood reactivity where mood brightens in response to positive events, paired with hypersomnia, hyperphagia or weight gain, leaden paralysis in limbs, and a long-standing pattern of interpersonal rejection sensitivity. Clinical Teaching: Depressive Specifiers and Rating Scales. Severity and Remission Specifiers. * **What it is:** Classification of a major depressive episode based on symptom count, symptom intensity, and degree of functional impairment, categorized as mild, moderate, moderately severe, or severe, with or without psychotic features. Remission status is specified as partial or full. * **Why boards care:** Severity dictates whether non-pharmacologic monotherapy is safe or if immediate psychotropic intervention or hospitalization is required. * **Must know criteria and timelines:** **PHQ-9** scoring ranges are 1 to 4 for minimal, 5 to 9 for mild, 10 to 14 for moderate, 15 to 19 for moderately severe, and 20 to 27 for severe depression. Diagnosis of a major depressive episode requires at least 5 of 9 SIGECAPS symptoms present for at least 2 weeks, representing a change from previous functioning, with at least one symptom being depressed mood or anhedonia. On the Zung scale, scores of 65 to 68 indicate moderate to severe depression. * **First-line approach:** **First-line** options for mild to moderate depression include psychotherapy alone, such as **cognitive behavioral therapy** or **interpersonal psychotherapy**, or antidepressant monotherapy. For severe depression with a **PHQ-9** score of 20 or higher, **first-line** treatment requires pharmacotherapy or combined medication and psychotherapy. * **Board trap:** **Board trap.** Selecting psychotherapy monotherapy for severe depression. Psychotherapy alone lacks evidence for severe depression and represents a classic board distractor. * **Safety alert:** **Safety alert.** Severe depression with a **PHQ-9** score of 20 or greater carries a significantly heightened risk for active suicidal ideation and intent, requiring immediate safety risk evaluation and determination of the appropriate care setting. Peripartum Onset Specifier. * **What it is:** Depressive episode occurring during pregnancy or in the immediate postpartum period. * **Why boards care:** Test writers evaluate your ability to manage maternal mental health safely while balancing fetal and neonatal drug exposure risks. * **Must know criteria and timelines:** Diagnostic criteria require mood symptom onset during pregnancy or within the first 4 weeks post-delivery. Up to 7% of pregnant women require antidepressant therapy during pregnancy. * **First-line approach:** **First-line** treatment for mild to moderate depression during pregnancy is evidence-based psychotherapy, specifically **interpersonal psychotherapy** or **cognitive behavioral therapy**. When pharmacotherapy is necessary due to severe symptoms, **sertraline** or **citalopram** are preferred SSRIs. * **Board trap:** **Board trap.** Assuming all psychotropic medications are strictly contraindicated during pregnancy or advising a patient to discontinue effective treatment without weighing relapse risks. Unmanaged maternal depression carries severe maternal and fetal risks. * **Safety alert:** **Safety alert.** **Lithium** is classified as Hale lactation risk category L4 and is contraindicated during breastfeeding due to significant infant toxicity risks from renal clearance differences and fluid shifts. **Electroconvulsive therapy** is safe and highly effective for severe, refractory depression or acute psychosis during pregnancy. Psychotic Features Specifier. * **What it is:** Severe depressive episode accompanied by delusions or hallucinations, which may be mood-congruent, such as guilt, poverty, or severe somatic delusions, or mood-incongruent. * **Why boards care:** Requires immediate combination pharmacotherapy or neuromodulation rather than standard antidepressant monotherapy. * **Must know criteria and timelines:** Presence of psychotic symptoms during an active severe major depressive episode. * **First-line approach:** **First-line** treatment mandates a combination of an antidepressant plus a second-generation antipsychotic, such as **olanzapine** or **quetiapine**, or **electroconvulsive therapy**. * **Board trap:** **Board trap.** Choosing antidepressant monotherapy or psychotherapy alone for psychotic depression. Psychotherapy alone has zero efficacy for psychotic depression. * **Safety alert:** **Safety alert.** Psychotic depression is a psychiatric emergency due to extreme suicide risk, command hallucinations, or profound functional incapacity, frequently necessitating inpatient psychiatric admission. Seasonal Pattern Specifier. * **What it is:** Recurrent depressive episodes demonstrating a clear temporal relationship between onset and a specific time of year. * **Why boards care:** Tests knowledge of non-pharmacologic chronotherapeutic interventions alongside standard antidepressant management. * **Must know criteria and timelines:** Depressive episodes occur at a specific time of year, most commonly autumn or winter, with full remissions occurring at predictable times, typically spring, demonstrated for at least 2 consecutive years without non-seasonal episodes during that period. * **First-line approach:** **First-line** interventions include **bright light therapy** using a 10,000 lux light box for 20 to 30 minutes every morning starting in early autumn, **vitamin D** supplementation at 2000 to 5000 IU daily, regular exercise, and SSRI pharmacotherapy. * **Board trap:** **Board trap.** Confusing seasonal pattern specifier with temporary holiday stress or adjustment disorder. Seasonal pattern requires recurrent full winter depressive episodes with spring remissions over consecutive years. Anxious Distress Specifier. * **What it is:** Depressive episode accompanied by prominent anxiety symptoms, including feeling keyed up or tense, unusual restlessness, difficulty concentrating due to worry, fear that something awful might happen, or fear of losing control. * **Why boards care:** Co-occurring anxious distress increases suicide risk, duration of illness, and treatment resistance. * **First-line approach:** **First-line** choices are SSRIs or SNRIs. * **Board trap:** **Board trap.** Prescribing **bupropion** as a first-line agent when severe anxious distress or panic is prominent. **Bupropion** can exacerbate severe anxiety, agitation, and restlessness. * **Safety alert:** **Safety alert.** Patients with major depressive disorder and anxious distress have higher rates of treatment failure and active suicidal ideation, requiring close safety monitoring during early treatment phases. Melancholic, Atypical, and Catatonic Specifiers. * **Melancholic Features:** Characterized by an inability to experience pleasure in all or almost all activities, lack of reactivity to usually pleasurable stimuli, depression that is regularly worse in the morning, early morning awakening at least 2 hours before usual, marked psychomotor retardation or agitation, significant anorexia or weight loss, and excessive or inappropriate guilt. **First-line** options include somatic treatments, including SSRIs, SNRIs, TCAs, and **electroconvulsive therapy**. * **Atypical Features:** Characterized by mood reactivity where mood brightens in response to actual or potential positive events, accompanied by two or more of: significant weight gain or increase in appetite, hypersomnia sleeping at least 10 hours daily, leaden paralysis feeling heavy in arms or legs, and a long-standing pattern of interpersonal rejection sensitivity. Historically responded well to MAOIs like **phenelzine**, though SSRIs or SNRIs are currently used first. * **With Catatonia Specifier:** Indicated when motor immobility, stupor, catalepsy, waxy flexibility, mutism, negativism, posturing, mannerisms, stereotypy, agitation, grimacing, echolalia, or echopraxia accompany the depressive episode. Responds to high-dose benzodiazepines like **lorazepam** or **electroconvulsive therapy**. Fitzgerald Sample Test Questions for This Leaf. Question 1. Which of the following statements is false regarding the diagnosis of major depression? * A. More likely to occur in men than women * B. Higher prevalence for whites than blacks * C. Lifetime prevalence is 12% * D. Risk factors include genetics and low education Pause. Answer. A. **Why It Is Correct:** Major depressive disorder affects women at twice the rate of men across the lifespan, making option A a false statement. **Why Each Distractor Fails:** * **A:** Correct choice for this negative stem because major depression is twice as common in women compared to men. * **B:** Incorrect choice because epidemiologic survey data in board review sources demonstrates a higher prevalence in whites than blacks. * **C:** Incorrect choice because 12% is the true established lifetime prevalence for major depressive disorder. * **D:** Incorrect choice because genetic family history and lower educational or socioeconomic status are established risk factors. Question 2. Karen, a 48-year-old married woman with two teenage children who works as an administrative assistant at the local community college, presents for concerns about irritability. You administer a PHQ-9 and she scores a 17. With this score, you assess that she has: * A. Mild depression * B. Moderately severe depression * C. Severe depression * D. No evidence of depression Pause. Answer. B. **Why It Is Correct:** On the **PHQ-9** rating scale, a score between 15 and 19 corresponds specifically to the moderately severe depression category. **Why Each Distractor Fails:** * **A:** Mild depression corresponds to a **PHQ-9** score range of 5 to 9. * **B:** Correct choice because a score of 17 falls squarely within the 15 to 19 range. * **C:** Severe depression requires a **PHQ-9** score of 20 to 27. * **D:** A score of 17 reflects substantial depressive symptom burden, making this choice incorrect. Question 3. Which of the following is not a DSM-5-TR criterion for a major depressive episode? * A. Hypersomnia * B. Loss of food enjoyment * C. Fatigue * D. Altered mood associated with bereavement Pause. Answer. D. **Why It Is Correct:** While bereavement can trigger a major depressive episode, altered mood associated with bereavement is not a distinct diagnostic criterion line-item for major depressive disorder in the DSM-5-TR. **Why Each Distractor Fails:** * **A:** Hypersomnia or insomnia is a valid sleep criterion under SIGECAPS. * **B:** Loss of food enjoyment or appetite change with weight fluctuation is a valid criterion under SIGECAPS. * **C:** Fatigue or loss of energy is a core criterion under SIGECAPS. * **D:** Correct choice for this negative stem because altered mood associated with bereavement is not a distinct DSM criterion line-item. Question 8. A 26-year-old married woman with a two-year-old daughter presents for evaluation of depression that she believes began after the birth of her daughter. She has a BDI score of 23. She relates that she is overall healthy and that she is 16 weeks pregnant. Which of the following would not be an appropriate course of action? * A. Advise no medication or psychotherapy at this time * B. Refer for weekly interpersonal psychotherapy * C. Initiate therapy with a therapeutic dose of citalopram * D. Prescribe a therapeutic dose of sertraline Pause. Answer. A. **Why It Is Correct:** Advising no treatment for a pregnant patient with active depression and a Beck Depression Inventory score of 23 is unsafe and inappropriate, because untreated maternal depression poses substantial risks to both mother and fetus. **Why Each Distractor Fails:** * **A:** Correct choice for this negative stem because advising no treatment is inappropriate and unsafe. * **B:** **Interpersonal psychotherapy** is an evidence-based **first-line** non-pharmacologic treatment during pregnancy. * **C:** **Citalopram** is an acceptable SSRI option during pregnancy when medication benefits outweigh risks. * **D:** **Sertraline** is a well-studied, preferred SSRI option during pregnancy and lactation. Question 13. A 28-year-old man who works at an accounting firm is being treated with paroxetine 20 mg for major depressive disorder. After six weeks, there is little improvement and he continues to feel depressed, having a difficult time focusing at work and low interest in his usual enjoyable activities. Prior to therapy, his Zung score was 68. Currently, his score is 65 and his symptoms are not remarkably different. After six weeks of paroxetine therapy, which of the following would not be recommended for this patient? * A. Increase the dose of paroxetine * B. Continue paroxetine and begin psychotherapy sessions * C. Switch to a therapeutic dose of venlafaxine * D. Discontinue paroxetine and start psychotherapy sessions Pause. Answer. D. **Why It Is Correct:** Discontinuing pharmacotherapy to rely on psychotherapy alone is not recommended for moderate-to-severe depression (indicated by a Zung score of 65 to 68), because psychotherapy monotherapy lacks evidence in moderate-to-severe or non-responsive depression. **Why Each Distractor Fails:** * **A:** Increasing the dose of **paroxetine** is a valid strategy to optimize initial treatment. * **B:** Augmenting antidepressant therapy with psychotherapy is a recommended evidence-based strategy for partial response. * **C:** Switching to another medication class, such as the SNRI **venlafaxine**, is an evidence-based option for inadequate response. * **D:** Correct choice for this negative stem because stopping medication for psychotherapy monotherapy in moderate-to-severe depression is inappropriate. Question 15. A 22-year-old male with type 1 diabetes mellitus and generalized anxiety disorder is currently being successfully treated for major depressive disorder, recurrent. He has been symptom-free for the past six months. He asks if he can stop taking his sertraline. You counsel that he has a high risk of recurrence because of which of the following? (Select all that apply) * A. Past episodes of depression * B. Presence of chronic medical condition * C. Co-occurring anxiety disorder * D. His age Pause. Answer. A, B, C, D (All choices apply) **Why It Is Correct:** All four factors independently elevate the risk of depressive recurrence: a history of recurrent episodes, comorbid type 1 diabetes, co-occurring generalized anxiety disorder, and early age of onset. **Why Each Distractor Fails:** * **A:** Multiple past episodes significantly increase lifetime recurrence risk. * **B:** Chronic medical conditions like diabetes double the risk of depressive relapse. * **C:** Comorbid anxiety disorders strongly predict chronic or recurrent depressive courses. * **D:** Onset at a younger age is an established risk factor for recurrent major depressive disorder. Question 16. Which of the following is false when considering a discontinuation of treatment for stable major depressive disorder? * A. Psychotherapy has less risk of relapse than psychopharmacotherapy * B. Treatment should be discontinued immediately rather than tapering doses * C. Patients should be educated on signs and symptoms of relapse * D. A follow-up visit should be scheduled two months following cessation of treatment Pause. Answer. B. **Why It Is Correct:** Discontinuing antidepressants immediately is false and unsafe; all psychotropic medications must be tapered over several weeks to avoid antidepressant discontinuation syndrome. **Why Each Distractor Fails:** * **A:** Psychotherapy builds long-term coping mechanisms and demonstrates lower relapse rates than medication discontinuation. * **B:** Correct choice for this negative stem because stopping medication abruptly without tapering is unsafe and false. * **C:** Educating patients and families on early warning signs of relapse is standard practice. * **D:** Scheduling a follow-up visit 2 months post-discontinuation evaluates stability and monitors for early relapse. Next. Topic. Differential: Bereavement vs MDD. Differential: Bereavement vs MDD. Bottom Line Summary. - **Major depressive disorder** requires at least 5 of 9 **SIGECAPS** symptoms present for at least 2 weeks, with at least 1 symptom being depressed mood or loss of interest or pleasure [1, 2]. - **Bereavement** involves feelings of emptiness and loss that occur in waves or pangs of grief associated with thoughts or memories of the deceased, rather than persistent depressed mood [3, 4]. - **Self-esteem** is generally preserved in normal **bereavement**, whereas pervasive worthlessness, self-loathing, and inappropriate guilt occur in **major depressive disorder** source 4. - **Suicidal ideation** in **bereavement** centers on joining the deceased, whereas in **major depressive disorder**, it stems from feeling worthless, unable to cope, or being a burden source 5. - In **DSM-5-TR**, bereavement does not exclude a diagnosis of **major depressive disorder** if full criteria of 5 of 9 symptoms for 2 weeks are met following a major loss [1, 2]. - **First-line** management for uncomplicated **bereavement** is supportive counseling and psychoeducation, whereas **major depressive disorder** requires evidence-based psychotherapy such as **CBT** or **IPT** and/or pharmacotherapy with **SSRIs** like **sertraline** or **escitalopram** [6-8]. Must-Know Concepts and Diagnostic Differentials. Bereavement vs. Major Depressive Disorder. - **Think:** Bereavement features waves of grief linked to memories with preserved self-esteem, whereas **major depressive disorder** features persistent, unremitting depressed mood and pervasive worthlessness [1, 4]. - **Priority:** Differentiate normal grief reactions from clinical depression to prevent unnecessary medication use or missing active suicide risk [5, 9]. - **Boards are testing:** Recognizing that bereavement is not a core **DSM-5-TR** criterion for **major depressive disorder**, and identifying when grief crosses into a clinical depressive episode [1, 10, 11]. Clinical Characteristics Contrast. - Mood pattern in bereavement: Depressed mood occurs in waves or pangs of grief triggered by reminders, interspersed with temporary periods of positive emotions and humor [3, 4]. - Mood pattern in **major depressive disorder**: Depressed mood is persistent, pervasive, and unremitting across a minimum 2-week timeline [1, 2]. - Thought content in bereavement: Preoccupation with thoughts and memories of the deceased source 4. - Thought content in **major depressive disorder**: Self-critical, self-reproachful, pessimistic, and ruminative self-blame source 4. - Self-esteem in bereavement: Preserved; self-derogation, if present, typically relates to perceived failures toward the deceased source 4. - Self-esteem in **major depressive disorder**: Marked feelings of worthlessness, self-loathing, and excessive or delusional guilt source 4. - **Safety alert:** Suicidal thoughts in bereavement focus on joining the deceased. Suicidal thoughts in **major depressive disorder** focus on ending life due to worthlessness, despair, or feeling like a burden source 5. Signposts and Board Pearls. - **First-line:** Supportive counseling, active listening, and monitoring are first-line for uncomplicated **bereavement**. **SSRIs** like **sertraline** or **escitalopram** and structured therapies like **CBT** or **IPT** are first-line for **major depressive disorder** [6-8]. - **Board trap:** Selecting bereavement as an automatic exclusion for diagnosing **major depressive disorder**. The **DSM-5-TR** removed the bereavement exclusion; clinicians must diagnose **major depressive disorder** if 5 of 9 **SIGECAPS** criteria for 2 weeks are present after a loss [1, 2]. - **Safety alert:** Never assume passive suicidal ideation after a major loss is benign grief. Perform an immediate assessment of ideation, intent, plan, and access to lethal means [5, 9]. Sample Board Practice Questions. Question 3. Which of the following is not a DSM-5-TR criterion for major depressive episode? - A. Hypersomnia - B. Loss of food enjoyment - C. Fatigue - D. Altered mood associated with bereavement Pause. Answer. D. - **Why it is correct:** Altered mood associated with bereavement is an expected life reaction to loss, not a formal diagnostic symptom in the **DSM-5-TR** criteria for a **major depressive episode** [1, 11]. - **Why the other choices are wrong:** - **A:** Hypersomnia is a valid sleep criterion under **SIGECAPS** (S) [12-14]. - **B:** Loss of food enjoyment reflects appetite change and anhedonia under **SIGECAPS** (A and I) [14-16]. - **C:** Fatigue is a valid energy loss criterion under **SIGECAPS** (E) [14, 17]. - **Test-taking pearl:** Board questions test exact **DSM-5-TR** criteria clusters. Normal grief or bereavement is a differential context, not a diagnostic criterion line-item [1, 11]. Active Recall Checkpoints. 1. What is the minimum timeline required for symptoms to meet criteria for a **major depressive episode**? 2. How do feelings of self-esteem differ between normal **bereavement** and **major depressive disorder**? 3. What is the core difference in suicidal ideation content between **bereavement** and **major depressive disorder**? 4. What 2 cardinal symptoms require at least 1 to be present to diagnose **major depressive disorder** under **SIGECAPS**? 5. Did the **DSM-5-TR** keep or remove the bereavement exclusion for diagnosing **major depressive disorder**? Next Study Step. - **Bipolar Disorder: criteria, mixed features, rapid cycling, mania vs hypomania**. Study this next to master screening for prior manic or hypomanic episodes before initiating antidepressant therapy for depression [10, 18, 19]. 💡 Would you like to review practice questions on bipolar spectrum differentials or dive into **SIGECAPS** vs **DIG FAST** mnemonics next? Next. Topic. Sample Question 16: Manifestation of Depression. Bottom Line Summary. * Diagnosis of **major depressive disorder** requires 5 or more symptoms present nearly every day for at least a 2-week period, with at least 1 core symptom being depressed mood or anhedonia [1, 2]. * Lifetime prevalence of **major depressive disorder** is 12 percent, affecting females twice as often as males, with a mean age of onset between 20 and 35 years [3, 4]. * Following symptom remission, antidepressant pharmacotherapy must be continued for 4 to 9 months during the continuation phase to prevent early relapse source 5. * Discontinuation of antidepressants requires a gradual taper over approximately 6 weeks to avoid **antidepressant discontinuation syndrome** [6, 7]. * Maintenance phase therapy is indicated for patients with 3 or more lifetime episodes of **major depressive disorder** or significant ongoing risk factors [8, 9]. * Psychotherapy alone is evidence-based for mild to moderate **major depressive disorder**, whereas severe depression requires pharmacotherapy or combination treatment [10, 11]. * Patients undergoing treatment discontinuation should be scheduled for a follow-up assessment 2 months after complete medication cessation source 12. High-Yield Concept Review: Depressive Disorders Manifestations, Criteria, and Discontinuation. Diagnostic Criteria and Clinical Timelines. Diagnosis of **major depressive disorder** requires a cluster of signs and symptoms lasting at least 2 weeks that cause significant functional impairment [1, 13, 14]. Clinicians utilize the **SIG E CAPS** mnemonic to evaluate the required 8 secondary domains: sleep disturbance, diminished interest, guilt or worthlessness, fatigue or loss of energy, impaired concentration, appetite or weight changes, psychomotor agitation or retardation, and suicidal ideation [1, 15, 16]. Children and adolescents frequently present with irritability as a mood equivalent rather than overt sadness [17, 18]. Differential Diagnoses and Specifiers. * **Persistent depressive disorder**: Chronic depressed mood present for at least 2 years in adults or 1 year in children, without a symptom-free interval exceeding 2 months source 19. * **Adjustment disorder with depressed mood**: Emotional or behavioral symptoms occurring within 3 months of an identifiable stressor that do not meet full criteria for **major depressive disorder** [20, 21]. * **Premenstrual dysphoric disorder**: Cyclic mood lability, irritability, or anxiety occurring during the luteal phase before menses and remitting shortly after onset of menses [22, 23]. High-Yield Exam Signposts. * **First-line**: **First-line** initial treatment for mild to moderate **major depressive disorder** includes **SSRIs**, **SNRIs**, or evidence-based psychotherapy such as **cognitive behavioral therapy** or **interpersonal psychotherapy** [10, 24]. * **Safety alert**: **Safety alert**: Never discontinue psychotropic medications abruptly or immediately prior to major stressful life events, as abrupt withdrawal triggers severe discontinuation symptoms and heightened relapse risk [6, 25]. * **Board trap**: **Board trap**: Assuming psychotherapy carries a higher relapse rate than medication when discontinuing care. In reality, psychotherapy teaches lasting cognitive and behavioral skill sets that provide lower long-term relapse rates than pharmacotherapy alone source 26. Fitzgerald Sample Test Question. Question 16. Which of the following is false when considering a discontinuation of treatment for stable **major depressive disorder**? source 27 A. Psychotherapy has less risk of relapse than psychopharmacotherapy source 27. B. Treatment should be discontinued immediately rather than tapering doses source 28. C. Patients should be educated on signs and symptoms of relapse source 28. D. A follow up visit should be scheduled two months following cessation of treatment source 28. Pause. **Quick Answer**: Statement B is false because psychotropic medications must be tapered gradually rather than stopped abruptly [6, 28]. **Key Clue**: The word false in the stem requires identifying the incorrect clinical management choice regarding treatment cessation [27, 28]. **Best Answer**: B. Treatment should be discontinued immediately rather than tapering doses source 28. **Why It Is Correct**: Option B is the false statement because psychotropic medications must always be tapered gradually over approximately 6 weeks to prevent **antidepressant discontinuation syndrome** [6, 7, 28]. Abrupt discontinuation causes bothersome flu-like symptoms, insomnia, nausea, dizziness, brain zaps, and heightened relapse risk [6, 25, 29]. **Why the Other Choices Are Wrong**: * **A**: This is a true statement because psychotherapy equips patients with enduring cognitive and behavioral coping mechanisms, resulting in lower relapse rates than medication discontinuation alone [26, 28]. * **C**: This is a true statement because educating patients and families on individual early warning signs enables rapid clinical intervention before full relapse occurs [28, 30, 31]. * **D**: This is a true statement because scheduling a follow-up visit 2 months after complete cessation ensures structured clinical evaluation during the highest risk window for recurrence [12, 28, 32]. **Test-Taking Pearl**: Always taper psychotropic medications over 6 weeks when discontinuing therapy, and schedule a 2-month follow-up visit to monitor for relapse [6, 12]. 🧠 Would you like to review the **FINISH** mnemonic for **antidepressant discontinuation syndrome** or move on to **Bipolar Disorder** criteria in Fitzgerald Chapter 8? Next. Topic. Sample Question 18: Gender Prevalence. FITZGERALD CH08 — Mood Disorders: Gender Prevalence and Depressive Criteria. Bottom Line Summary. * **Lifetime prevalence**: **Major depressive disorder** has a lifetime prevalence of 12% in the general population. * **Gender ratio**: Women have twice the risk of **major depressive disorder** compared to men, establishing a 2 to 1 female-to-male prevalence ratio. * **Age distribution**: The mean age of onset for **major depressive disorder** is 20 to 35 years. Prevalence in young adults aged 18 to 29 years is 3 times higher than in adults over 60 years of age. * **Genetic risk**: Heritability is approximately 40%. First-degree biological relatives of individuals with **major depressive disorder** face a 2 to 4 times higher risk than the general population. * **Socioeconomic risk**: Lower education level and lower socioeconomic status are recognized demographic risk factors. * **Medical inpatient risk**: Hospitalized medical inpatients experience a 15% higher risk of **major depressive disorder** than the general population. * **Diagnostic criteria and timeline**: Diagnosis requires 5 or more symptoms present nearly every day for at least a 2-week period representing a functional change. At least 1 core symptom must be depressed mood or loss of interest or pleasure (**anhedonia**). * **Episode duration and conversion**: Untreated depressive episodes last 6 to 13 months. Between 5% and 10% of patients initially diagnosed with **major depressive disorder** experience a manic episode 6 to 10 years later, shifting their diagnosis to **bipolar disorder**. High-Yield Clinical Teaching. **Major depressive disorder** is a cyclic, recurring condition characterized by a cluster of signs and symptoms where pathologic depressed mood or **anhedonia** causes significant social, occupational, or interpersonal disruption. Demographics and Risk Architecture. * **Gender**: Female gender is a major risk factor. Women are diagnosed at twice the rate of men. * **Age**: Depression is predominantly a disease of younger populations. Prevalence declines as age increases beyond age 60. * **Race**: Epidemiological data in Fitzgerald indicates a higher reported prevalence for whites than blacks. * **Medical Setting**: Physical illness increases vulnerability. Medical inpatients demonstrate a 15% higher risk of depression compared to community baselines. * **Comorbidities**: High rates of comorbidity exist with learning disabilities, **ADHD**, **anxiety disorders**, **PTSD**, conduct disorder, and **substance use disorders**. Key Signposts for Board Mastery. * **Safety alert**: Always screen for past manic or hypomanic episodes before diagnosing unipolar depression or prescribing psychotropics. Up to 10% of patients presenting with unipolar depression eventually experience a manic episode 6 to 10 years later. Prescribing an antidepressant as monotherapy in an unrecognized bipolar patient can trigger acute mania or rapid cycling. * **Board trap**: Assuming older adults have the highest overall prevalence of **major depressive disorder**. Board test-writers frequently exploit this misconception. While depression in older adults carries unique risks, the highest overall prevalence occurs in young adults aged 18 to 29 years. * **First-line**: For mild to moderate **major depressive disorder**, first-line evidence-based options include psychotherapy alone (such as **cognitive behavioral therapy** or **interpersonal psychotherapy**), pharmacotherapy alone (such as an **SSRI**), or combination therapy. Fitzgerald Chapter 8 Sample Question. Question 1. Which of the following statements is false regarding the diagnosis of **major depression**? A) More likely to occur in men than women B) Higher prevalence for whites than blacks C) Lifetime prevalence is 12% D) Risk factors include genetics and low education Pause. Answer: A Key Clue. The question stem asks for the false statement regarding epidemiological risk factors and prevalence of **major depressive disorder**. Best Answer. A) More likely to occur in men than women Why It Is Correct. Statement A is false, making it the correct selection for this negative stem. **Major depressive disorder** is twice as common in women as in men (2 to 1 female-to-male ratio). Why the Other Choices Are Wrong. * **A:** This choice is false in clinical reality, which makes it the correct answer to the question stem. Females carry two times the lifetime risk of males. * **B:** This choice is incorrect because the statement is true. Epidemiological data presented in Fitzgerald indicates a higher reported prevalence of **major depressive disorder** for whites than blacks. * **C:** This choice is incorrect because the statement is true. The population lifetime prevalence for **major depressive disorder** is 12%. * **D:** This choice is incorrect because the statement is true. Established risk factors include genetic predisposition (40% heritability, 2 to 4 times higher risk in first-degree relatives) and lower educational attainment. Test-Taking Pearl. When a board question asks for a false statement, reframe each option as true or false. The single false statement is your target answer. Additional High-Yield Exam Recall Items. Question 2. A 22-year-old male with **type 1 diabetes mellitus** and **generalized anxiety disorder** achieves complete remission from a second episode of **major depressive disorder** after six months of **sertraline** therapy. He asks if he can discontinue his medication. What is the best clinical reasoning regarding his recurrence risk? A) His risk is low because he has been symptom free for six months. B) His risk is high due to his young age, past depressive episodes, co-occurring medical condition, and comorbid anxiety disorder. C) His risk is low because his diabetes is well managed. D) His risk is high solely because **sertraline** causes rapid tolerance. Pause. Answer: B Key Clue. The stem describes a young patient with multiple established risk factors for depressive recurrence, including prior episodes, young age, chronic physical illness, and comorbid anxiety. Best Answer. B) His risk is high due to his young age, past depressive episodes, co-occurring medical condition, and comorbid anxiety disorder. Why It Is Correct. Recurrence risk increases significantly in the presence of persistent mild symptoms, multiple past depressive episodes, early age of onset, co-occurring non-affective psychiatric conditions (**generalized anxiety disorder**), and general medical conditions (**type 1 diabetes mellitus**). Maintenance therapy is strongly indicated for patients with three or more episodes or those with significant cumulative risk factors. Why the Other Choices Are Wrong. * **A:** Incorrect. Six months of symptom remission marks the continuation phase, but multiple underlying risk factors still predict high long-term recurrence rates (50% to 85% lifetime recurrence). * **B:** Correct. Young age, recurrent episodes, chronic medical illness, and co-occurring anxiety interact to raise the risk of relapse. * **C:** Incorrect. Medical comorbidities increase depressive recurrence risk regardless of baseline glycemic control. * **D:** Incorrect. **Sertraline** does not cause pharmacological tolerance; the risk is driven by disease biology and demographic factors. Test-Taking Pearl. In board scenarios evaluating maintenance therapy, count the patient's risk factors. Multiple psychiatric or medical comorbidities plus early onset signal a clear need for ongoing maintenance pharmacotherapy. Next Study Step. Proceed to **Major Depressive Disorder: Criteria and Screening (SIG E CAPS Mnemonic and PHQ Scoring)** to master diagnostic symptom thresholds and severity rating scales for exam day. Next. End of this drive.